{"organizations": [], "uuid": "ebd77314c72da4851d10f2316b1e20d6c26c973f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180306.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-clearside-biomedical-provides-upda/brief-clearside-biomedical-provides-update-on-two-phase-3-clinical-trials-of-cls-ta-in-retinal-vein-occlusion-idUSASB0C8XY", "country": "US", "domain_rank": 408, "title": "BRIEF-Clearside Biomedical Provides Update On Two Phase 3 Clinical Trials Of CLS-TA In Retinal Vein Occlusion", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.004, "site_type": "news", "published": "2018-03-06T20:43:00.000+02:00", "replies_count": 0, "uuid": "ebd77314c72da4851d10f2316b1e20d6c26c973f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-clearside-biomedical-provides-upda/brief-clearside-biomedical-provides-update-on-two-phase-3-clinical-trials-of-cls-ta-in-retinal-vein-occlusion-idUSASB0C8XY", "ord_in_thread": 0, "title": "BRIEF-Clearside Biomedical Provides Update On Two Phase 3 Clinical Trials Of CLS-TA In Retinal Vein Occlusion", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "clearside biomedical inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6 (Reuters) - Clearside Biomedical Inc:\n* CLEARSIDE BIOMEDICAL PROVIDES UPDATE ON TWO PHASE 3 CLINICAL TRIALS OF CLS-TA IN RETINAL VEIN OCCLUSION\n* CLEARSIDE BIOMEDICAL INC - ‍NOW EXPECTS TO REPORT PRELIMINARY DATA FROM SAPPHIRE TRIAL IN Q4 OF 2018 INSTEAD OF Q1 OF 2019​\n* CLEARSIDE BIOMEDICAL - ‍IF PRIMARY ENDPOINTS MET IN BOTH TOPAZ AND SAPPHIRE TRIALS, CO EXPECTS TO SEEK AGNOSTIC LABEL IN U.S. Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-06T20:43:00.000+02:00", "crawled": "2018-03-07T19:47:49.033+02:00", "highlightTitle": ""}